Virulizin® - a review of its antineoplastic activity

Bibliography

• PARKER SL, TONG T, BOLDEN S et al.: Cancer statistics, 1997. CA Cancer J. Clin. (1994) 47:5–27.
   Web of Science ®Google Scholar
• BRAND RE, TEMPERO MA: Pancreatic cancer. Curr. Opin. Oncol (1998) 10:362–366.
   PubMedGoogle Scholar
• YEO CJ: Pancreatic cancer: 1998 update. J. Am. Coll. Surg. (1998) 187:429–442.
   PubMed Web of Science ®Google Scholar
• REGINE WF, JOHN WJ, MOHIUDDIN M: Current and emerging treatment for pancreatic cancer. Drugs Aging (1997) 11:285–295.
   PubMed Web of Science ®Google Scholar
• WARSHAW AL, CASTILLO CFD: Pancreatic carcinoma. New Engl. J. Med. (1992) 326:455–465.
   PubMed Web of Science ®Google Scholar
• CONTON KC, KLIMSTRA DS, BRENNAN MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann. Surg. (1996) 223:273–279.
   PubMed Web of Science ®Google Scholar
• SCHNALL SF, MACDONALD JS: Chemotherapy of adenocarcinoma of pancreas. Semin. Oncol (1996) 23:220–228.
   PubMed Web of Science ®Google Scholar
• BURRIS III HA, MOORE MJ, ANDERSEN J et al.: Improve-ment in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403–2413.
   PubMed Web of Science ®Google Scholar
• VON HOFF DD, GOODWIN AL, GARCIA A: Advances inthe treatment of patients with pancreatic cancer: in symptoms and survival time. The San Antonio Drug Development Team. Br. J. Cancer (1998) 78\(Suppl. 3):9–13.
   Google Scholar
• CARMICHAEL J: Clinical response benefits in patients with advanced pancreatic cancer. Role of gemcitabine. Digestion (1997) 58:503–507.
   PubMed Web of Science ®Google Scholar
• MOORE M: Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review. Cancer (1996) 78\(Suppl. 3):633–638.
   Google Scholar
• VELDERS MP, SCHREIBER H, KAST WM: Active immuni-zation against cancer cells: impediments and advances. Semin. Oncol. (1998) 25:697–706.
   PubMed Web of Science ®Google Scholar
• BUTERA J, MALACHOVSKY M, RATHORE R et al.: Novel approaches in development for the treatment of pancreatic cancer. Front. Biosci. (1998) 3:E226–229.
   PubMedGoogle Scholar
• SCHMIEGEL W: Biological response modifier-immunotherapeutic approaches in pancreatic cancer. Hepatogastroenterology (1989) 36:456–458.
   PubMed Web of Science ®Google Scholar
• DAMIA G, TAGLIABUE G, ALLAVENA P et al.: Flavone acetic acid antitumor activity against a mouse pancre-atic adenocarcinoma is mediated by natural killer cells. Cancer Immunol. Immunother. (1990) 32:241–244.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, SCHUTTE M, GOSSETT J et al.: Development and characterization of cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. (1998) 4:194–203.
   PubMed Web of Science ®Google Scholar
• CLARY BM, COVENEY EC, BLAZER III DG et al.: Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines. Surgery (1990) 120:174–181.
   Google Scholar
• HEMMILA MR, CHANG AE: Clinical implications of the new biology in the development of melanoma vaccines. J. Surg. Oncol. (1999) 70:263–274.
   PubMed Web of Science ®Google Scholar
• KAWAKAMI Y: Immunotherapy using T cell defined tumor antigens for melanoma. Microbiol. Immuno. (1998) 42:801–813.
   PubMed Web of Science ®Google Scholar
• MARINCOLA FM, DAPOZZO LF, DRUCKER BJ et al: Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model. Surgery (1990) 108:919–929.
   PubMed Web of Science ®Google Scholar
• PEIPER M, NAGOSHI M, PATEL D et al.: Human pancre-atic cancer cells (Mpanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int. J. Cancer (1997) 71:993–999.
   PubMed Web of Science ®Google Scholar
• HERSH EM, STOPECK AT: Advances in the biologicaltherapy and gene therapy of malignant disease. Clin. Cancer Res. ( 1997) 3(12 Pt 2):2623–2629.
   Google Scholar
• TEMPERO MA, PUR RM, UCHIDA E et al: Monoclonalantibody C012-1A and leukopheresis in immuno-therapy of pancreatic cancer. Hybridoma (1986) 5 (Suppl. D:5133.
   Google Scholar
• KLAPDOR MB, MUHRER KH, MALFERTHEINER P et al. The German multicentric Phase I-II trial of monoclonal antibody treatment in advanced pancre-atic cancer. Digestion (1988) 40:72.
   Web of Science ®Google Scholar
• VON HOFF DD, FLEMING TR, MACDONALD JS et al.: Phase II evaluation of recombinant a-interferon in patients with advanced pancreatic carcinoma: a Southwest Oncology Group Study. J. Biol. Response Mod. 9:584–587.
   Google Scholar
• BROWN TD, GOODMAN P, FLEMING T eta].: Phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of pancreas: a Southwest Oncology Group Study. J. Immunotherapy (1991) 10:336–388.
   Google Scholar
• LANG PG JR: Malignant melanoma. Med. Clin. North Am. (1998) 82:1325–1358.
   PubMed Web of Science ®Google Scholar
• DMOWSKI WP, GEBEL HM, BRAUN DP: The role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet. Gynecol. Scand. (1994) 73 (Suppl.):7–14.
   Google Scholar
• FALUS A, MERETEY K: Histamine: an early messenger ininflammatory and immune reactions. Immunol. Today (1992) 13:154–156.
   PubMedGoogle Scholar
• MIZEL SB: The interleukins. FASEB J. (1989) 13:2379–2388.
   Google Scholar
• PHIPPS RP, STEIN SH, ROPER RL: A new view of prosta-glandin E regulation of the immune response. Immunol. Today (1991) 12:349–352.
   PubMedGoogle Scholar
• UOTILA P: Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. Cancer Immuno. Immunother. (1993) 37:251–254.
   PubMed Web of Science ®Google Scholar
• TUCKER ON, DANNENBERG AJ, YANG EK et al.: Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. (1999) 59:987–990.
   PubMed Web of Science ®Google Scholar
• CHAN G, BOYLE JO, YANG EK et al: Cyclooxygenase-2expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. (1999) 59:991–994.
   PubMed Web of Science ®Google Scholar
• BRAUN DP, HARRIS J: The impact of prostaglandins on cancer patient immunity. In: Prostaglandin Inhibitors in Tumour Immunology and Immunotherapy. Harris, Braun, Anderson (Eds.), CRC Press, Boca Raton, FLA, USA (1994):109–129.
   Google Scholar
• BRAUN DP, SIZIOPIKOU, KP, CASEY LC, HARRIS JE: The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon-y in the peripheral blood monocytes of patients with solid tumors: modulation by arachidonic acid metabolic inhibitors. Cancer Immunol Immuno-ther. (1990) 32:55–61.
   PubMed Web of Science ®Google Scholar
• BRAUN DP, AHN MC, HARRIS JE et al.: Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism. Cancer Res. (1993) 53:3362–3368.
   PubMed Web of Science ®Google Scholar
• SCHULTZ RM, MERRIMAN RL, TOTH JE et al: Evaluationof new anticancer agents against the MIA PaCa-2 and PANC- 1 human pancreatic carcinoma xenografts. Oncol. Res. (1993) 5:223–228.
   PubMed Web of Science ®Google Scholar
• MERRIMAN RL, HERTEL LW, SCHULTZ RM et al.: Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest. New. Drugs (1996) 14:243–247.
   PubMed Web of Science ®Google Scholar
• THIRLWELL M, BOOS G, TRUJILLO R eta].: Phase I-II trial of an unconventional agent, Virulizin®, in patients with advanced cancer. Union Internationale Contre le Cancer (UICC). Hamburg, Germany (August, 1990).
   Google Scholar
• THIRLWELL M, TRUDEAU M, TRUJILLO R et al: Phase I-II trial of an unconventional agent, Virulizin, in patients with advanced cancer. Proc Am. Soc. Clin. Oncol. (1991) 10:333. 1177.
   Google Scholar
• WARNER E, WEINROTH J, CHANG S et al.: Phase II trial of Virulizin in patients with pancreatic cancer. Clin. Invest. Med. (1994) 17:37–41.
   PubMed Web of Science ®Google Scholar
• LIU C, MAO H, JOSHI SS et al.: A novel immunothera-peutic agent for pancreatic cancer: results of preclinical and clinical trials using Virulizin. Proceed-ings of the 90th Annual Meeting of AACR (1999) 40:575.
   Google Scholar
• ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. (1996) 7:347–353.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improve-ments in survival and clinical benefit with gemcita-bine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol (1997) 15:2403–2413.
   PubMed Web of Science ®Google Scholar
• DE LA GARZA JG, GUTIERREZ D, GALLARDO D et al.: Phase II trial of a new agent Virulizin in patients with advanced malignant melanoma (preliminary report). Baylor College of Medicine Research Symposium. Houston, Texas (15 April 1993).
   Google Scholar